Tags

Type your tag names separated by a space and hit enter

Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial.
Support Care Cancer. 2007 Mar; 15(3):301-7.SC

Abstract

GOALS

The aim of the study was to assess the impact of an eicosapentanoic acid-containing protein and energy dense oral nutritional supplement (EPA-ONS) on nutritional and inflammatory status, quality of life (QOL), plasma phospholipids (PPL) and cytokine profile, tolerance of irinotecan-containing chemotherapy and EPA-ONS in patients with advanced colorectal cancer (CRC) receiving chemotherapy.

MATERIALS AND METHODS

Patients with advanced CRC having one prior chemotherapy regimen received 480 ml of EPA-ONS daily for 3 weeks before commencing chemotherapy with folinic acid, 5-fluorouracil, irinotecan (FOLFIRI), and continued for 3 cycles of treatment (9 weeks). All assessments including weight, body composition, C-reactive protein (CRP), QOL, dietary intake, PPL and cytokine analyses were performed at baseline, 3 and 9 weeks.

RESULTS

Twenty-three patients were enrolled, 20 completed 3 weeks, and 15 completed 9 weeks. The mean EPA-ONS intake was 1.7 tetrapaks (408 ml) daily. There was a significant increase in mean weight (2.5 kg) at 3 weeks (p=0.03). Lean body mass (LBM) was maintained. Protein and energy intake significantly decreased after the commencement of chemotherapy (protein p=0.003, energy p=0.02). There was a significant increase in energy levels (p=0.03), whilst all other QOL measures were maintained. PPL EPA levels increased significantly over the first 3 weeks. Mean CRP increased by 14.9 mg/L over the first 3 weeks (p=0.004), but decreased to baseline levels by the end of the trial. There was a significant correlation between plasma IL-6 and IL-10 concentrations and survival, and between IL-12 and toxicity.

CONCLUSION

Dietary counseling and the provision of EPA-ONS may result in maintenance of nutritional status and QOL, however randomized trials are required to evaluate the impact of EPA on toxicity from chemotherapy.

Authors+Show Affiliations

Sydney Cancer Centre, Royal Prince Alfred Hospital and Concord Hospital, Sydney, Australia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase II
Journal Article

Language

eng

PubMed ID

17021855

Citation

Read, Jane A., et al. "Nutrition Intervention Using an Eicosapentaenoic Acid (EPA)-containing Supplement in Patients With Advanced Colorectal Cancer. Effects On Nutritional and Inflammatory Status: a Phase II Trial." Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, vol. 15, no. 3, 2007, pp. 301-7.
Read JA, Beale PJ, Volker DH, et al. Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. Support Care Cancer. 2007;15(3):301-7.
Read, J. A., Beale, P. J., Volker, D. H., Smith, N., Childs, A., & Clarke, S. J. (2007). Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, 15(3), 301-7.
Read JA, et al. Nutrition Intervention Using an Eicosapentaenoic Acid (EPA)-containing Supplement in Patients With Advanced Colorectal Cancer. Effects On Nutritional and Inflammatory Status: a Phase II Trial. Support Care Cancer. 2007;15(3):301-7. PubMed PMID: 17021855.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Nutrition intervention using an eicosapentaenoic acid (EPA)-containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. AU - Read,Jane A, AU - Beale,Philip J, AU - Volker,Dianne H, AU - Smith,Narelle, AU - Childs,Annabel, AU - Clarke,Stephen J, Y1 - 2006/10/05/ PY - 2006/03/24/received PY - 2006/08/23/accepted PY - 2006/10/6/pubmed PY - 2007/8/11/medline PY - 2006/10/6/entrez SP - 301 EP - 7 JF - Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer JO - Support Care Cancer VL - 15 IS - 3 N2 - GOALS: The aim of the study was to assess the impact of an eicosapentanoic acid-containing protein and energy dense oral nutritional supplement (EPA-ONS) on nutritional and inflammatory status, quality of life (QOL), plasma phospholipids (PPL) and cytokine profile, tolerance of irinotecan-containing chemotherapy and EPA-ONS in patients with advanced colorectal cancer (CRC) receiving chemotherapy. MATERIALS AND METHODS: Patients with advanced CRC having one prior chemotherapy regimen received 480 ml of EPA-ONS daily for 3 weeks before commencing chemotherapy with folinic acid, 5-fluorouracil, irinotecan (FOLFIRI), and continued for 3 cycles of treatment (9 weeks). All assessments including weight, body composition, C-reactive protein (CRP), QOL, dietary intake, PPL and cytokine analyses were performed at baseline, 3 and 9 weeks. RESULTS: Twenty-three patients were enrolled, 20 completed 3 weeks, and 15 completed 9 weeks. The mean EPA-ONS intake was 1.7 tetrapaks (408 ml) daily. There was a significant increase in mean weight (2.5 kg) at 3 weeks (p=0.03). Lean body mass (LBM) was maintained. Protein and energy intake significantly decreased after the commencement of chemotherapy (protein p=0.003, energy p=0.02). There was a significant increase in energy levels (p=0.03), whilst all other QOL measures were maintained. PPL EPA levels increased significantly over the first 3 weeks. Mean CRP increased by 14.9 mg/L over the first 3 weeks (p=0.004), but decreased to baseline levels by the end of the trial. There was a significant correlation between plasma IL-6 and IL-10 concentrations and survival, and between IL-12 and toxicity. CONCLUSION: Dietary counseling and the provision of EPA-ONS may result in maintenance of nutritional status and QOL, however randomized trials are required to evaluate the impact of EPA on toxicity from chemotherapy. SN - 0941-4355 UR - https://www.unboundmedicine.com/medline/citation/17021855/Nutrition_intervention_using_an_eicosapentaenoic_acid__EPA__containing_supplement_in_patients_with_advanced_colorectal_cancer__Effects_on_nutritional_and_inflammatory_status:_a_phase_II_trial_ L2 - https://dx.doi.org/10.1007/s00520-006-0153-3 DB - PRIME DP - Unbound Medicine ER -